Vegf inhibition, hypertension, and renal toxicity

Suzanne R. Hayman, Nelson Leung, Joseph Peter Grande, Vesna D Garovic

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

The use of anti-angiogenic agents as part of the therapeutic armamentarium for advanced stage solid tumors has become the standard of care in several instances, particularly for renal cell carcinoma, non-small cell lung carcinoma, colorectal carcinoma, and gastrointestinal stromal tumors. These agents primarily target vascular endothelial growth factor (VEGF) and/or its receptors, and include bevacizumab, a humanized monoclonal antibody against VEGF, as well as tyrosine kinase inhibitors that target several receptor tyrosine kinases (RTK), including VEGF receptors. These therapies, as a general class of anti-angiogenic medications, have been shown to have common adverse vascular effects attributable directly or indirectly to their anti-VEGF effects, including hypertension, renal vascular injury, often manifested by proteinuria and thrombotic microangiopathy, and congestive heart failure. Knowledge of these common side effects and their underlying mechanisms may allow for more accurate and prompt diagnoses, timely clinical interventions, and the development of rational and standard treatments. These measures may minimize patient morbidity and mortality, not only by the treatment of side effects, but also by minimizing the disruption of treatment of the underlying malignancy, as well as improving patient quality of life.

Original languageEnglish (US)
Pages (from-to)285-294
Number of pages10
JournalCurrent Oncology Reports
Volume14
Issue number4
DOIs
StatePublished - Aug 2012

Fingerprint

Renal Hypertension
Vascular Endothelial Growth Factor A
Thrombotic Microangiopathies
Therapeutics
Antibodies, Monoclonal, Humanized
Vascular Endothelial Growth Factor Receptor
Gastrointestinal Stromal Tumors
Vascular System Injuries
Receptor Protein-Tyrosine Kinases
Standard of Care
Proteinuria
Renal Cell Carcinoma
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Blood Vessels
Colorectal Neoplasms
Neoplasms
Heart Failure
Quality of Life
Morbidity

Keywords

  • Bevacizumab
  • Hypertension
  • Podocyturia
  • Proteinuria
  • Renal toxicity
  • Thrombotic microangiopathy
  • Tyrosine kinase inhibitors
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology

Cite this

Vegf inhibition, hypertension, and renal toxicity. / Hayman, Suzanne R.; Leung, Nelson; Grande, Joseph Peter; Garovic, Vesna D.

In: Current Oncology Reports, Vol. 14, No. 4, 08.2012, p. 285-294.

Research output: Contribution to journalArticle

Hayman, Suzanne R. ; Leung, Nelson ; Grande, Joseph Peter ; Garovic, Vesna D. / Vegf inhibition, hypertension, and renal toxicity. In: Current Oncology Reports. 2012 ; Vol. 14, No. 4. pp. 285-294.
@article{c376da2b86f74e258400a706f8612617,
title = "Vegf inhibition, hypertension, and renal toxicity",
abstract = "The use of anti-angiogenic agents as part of the therapeutic armamentarium for advanced stage solid tumors has become the standard of care in several instances, particularly for renal cell carcinoma, non-small cell lung carcinoma, colorectal carcinoma, and gastrointestinal stromal tumors. These agents primarily target vascular endothelial growth factor (VEGF) and/or its receptors, and include bevacizumab, a humanized monoclonal antibody against VEGF, as well as tyrosine kinase inhibitors that target several receptor tyrosine kinases (RTK), including VEGF receptors. These therapies, as a general class of anti-angiogenic medications, have been shown to have common adverse vascular effects attributable directly or indirectly to their anti-VEGF effects, including hypertension, renal vascular injury, often manifested by proteinuria and thrombotic microangiopathy, and congestive heart failure. Knowledge of these common side effects and their underlying mechanisms may allow for more accurate and prompt diagnoses, timely clinical interventions, and the development of rational and standard treatments. These measures may minimize patient morbidity and mortality, not only by the treatment of side effects, but also by minimizing the disruption of treatment of the underlying malignancy, as well as improving patient quality of life.",
keywords = "Bevacizumab, Hypertension, Podocyturia, Proteinuria, Renal toxicity, Thrombotic microangiopathy, Tyrosine kinase inhibitors, Vascular endothelial growth factor",
author = "Hayman, {Suzanne R.} and Nelson Leung and Grande, {Joseph Peter} and Garovic, {Vesna D}",
year = "2012",
month = "8",
doi = "10.1007/s11912-012-0242-z",
language = "English (US)",
volume = "14",
pages = "285--294",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Vegf inhibition, hypertension, and renal toxicity

AU - Hayman, Suzanne R.

AU - Leung, Nelson

AU - Grande, Joseph Peter

AU - Garovic, Vesna D

PY - 2012/8

Y1 - 2012/8

N2 - The use of anti-angiogenic agents as part of the therapeutic armamentarium for advanced stage solid tumors has become the standard of care in several instances, particularly for renal cell carcinoma, non-small cell lung carcinoma, colorectal carcinoma, and gastrointestinal stromal tumors. These agents primarily target vascular endothelial growth factor (VEGF) and/or its receptors, and include bevacizumab, a humanized monoclonal antibody against VEGF, as well as tyrosine kinase inhibitors that target several receptor tyrosine kinases (RTK), including VEGF receptors. These therapies, as a general class of anti-angiogenic medications, have been shown to have common adverse vascular effects attributable directly or indirectly to their anti-VEGF effects, including hypertension, renal vascular injury, often manifested by proteinuria and thrombotic microangiopathy, and congestive heart failure. Knowledge of these common side effects and their underlying mechanisms may allow for more accurate and prompt diagnoses, timely clinical interventions, and the development of rational and standard treatments. These measures may minimize patient morbidity and mortality, not only by the treatment of side effects, but also by minimizing the disruption of treatment of the underlying malignancy, as well as improving patient quality of life.

AB - The use of anti-angiogenic agents as part of the therapeutic armamentarium for advanced stage solid tumors has become the standard of care in several instances, particularly for renal cell carcinoma, non-small cell lung carcinoma, colorectal carcinoma, and gastrointestinal stromal tumors. These agents primarily target vascular endothelial growth factor (VEGF) and/or its receptors, and include bevacizumab, a humanized monoclonal antibody against VEGF, as well as tyrosine kinase inhibitors that target several receptor tyrosine kinases (RTK), including VEGF receptors. These therapies, as a general class of anti-angiogenic medications, have been shown to have common adverse vascular effects attributable directly or indirectly to their anti-VEGF effects, including hypertension, renal vascular injury, often manifested by proteinuria and thrombotic microangiopathy, and congestive heart failure. Knowledge of these common side effects and their underlying mechanisms may allow for more accurate and prompt diagnoses, timely clinical interventions, and the development of rational and standard treatments. These measures may minimize patient morbidity and mortality, not only by the treatment of side effects, but also by minimizing the disruption of treatment of the underlying malignancy, as well as improving patient quality of life.

KW - Bevacizumab

KW - Hypertension

KW - Podocyturia

KW - Proteinuria

KW - Renal toxicity

KW - Thrombotic microangiopathy

KW - Tyrosine kinase inhibitors

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84865658329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865658329&partnerID=8YFLogxK

U2 - 10.1007/s11912-012-0242-z

DO - 10.1007/s11912-012-0242-z

M3 - Article

C2 - 22544560

AN - SCOPUS:84865658329

VL - 14

SP - 285

EP - 294

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 4

ER -